Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q969U7
UPID:
PSMG2_HUMAN
Alternative names:
Hepatocellular carcinoma-susceptibility protein 3; Tumor necrosis factor superfamily member 5-induced protein 1
Alternative UPACC:
Q969U7; B0YJB3; Q6IAH4; Q9NRV1; V9GYH7
Background:
Proteasome assembly chaperone 2 (PAC2), also known as Hepatocellular carcinoma-susceptibility protein 3 and Tumor necrosis factor superfamily member 5-induced protein 1, plays a pivotal role in cellular function by promoting the assembly of the 20S proteasome. This process is crucial for protein degradation and turnover, which is essential for maintaining cellular homeostasis. PAC2, in a heterodimer with PSMG1, binds to proteasome subunits PSMA5 and PSMA7, facilitating the assembly of the proteasome alpha subunits into the alpha ring and preventing its dimerization.
Therapeutic significance:
PAC2's involvement in Proteasome-associated autoinflammatory syndrome 4, a disorder characterized by panniculitis, erythematous skin lesions, and various systemic symptoms, underscores its therapeutic significance. Understanding the role of PAC2 could open doors to potential therapeutic strategies for this autoinflammatory disorder and related conditions.